Sandoz Generics Claims Survive, Despite Post-Mensing Trend
An Ohio federal judge ruled Friday that design defect claims brought against Sandoz Inc. by a man allegedly blinded by its generic arrhythmia drug are not preempted by federal law, putting...To view the full article, register now.
Already a subscriber? Click here to view full article